#ASCO22 – RCT: Triplet therapy, transplantation, and maintenance until progression in myeloma.

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Improved progression-free survival in multiple myeloma patients following three-drug therapy with autologous stem cell transplant – Dana-Farber Cancer Institute

Commentary on Twitter

DETERMINATION: Among adults with multiple myeloma, continuous lenalidomide maintenance therapy after triplet therapy (RVD, plus ASCT) associated with longer PFS than triplet therapy alone. #ASCO22 https://t.co/YhKgjc1Enz pic.twitter.com/cU8nefokZo

— NEJM (@NEJM) June 5, 2022